Study found increase in RSV-associated hospitalizations in premature babies in N.S.
The policy was reversed in 2023, when a new RSV vaccine for infants was introduced. Halifax pediatric infectious disease physician Joanne Langley said the study shows why it's crucial to examine the effects of health-care changes and to do more to prevent infants from contracting RSV.
"We wanted to make sure that there weren't a lot of children that would be harmed by that policy," said Langley, who led the study. "And what we found is that there was a much higher number of admissions when we restricted access to the antibody."
RSV, which stands for respiratory syncytial virus, is a common and highly contagious respiratory infection that is especially dangerous to infants and older people.
Up until 2016, babies in Nova Scotia born at 32 weeks gestation or less were eligible for palivizumab, a vaccine administered in four or five doses in an RSV season.
But that year, the IWK children's hospital in Halifax dropped that eligibility down to 30 weeks and under, in line with Canadian Paediatric Society recommendations at the time.
'You feel helpless'
Langley's team examined that two-week change to eligibility using provincial databases. In a study published this month, they found hospitalizations linked to RSV in Nova Scotia spiked in premature infants born at 30 to 32 weeks gestation between 2016 and 2019. There were no deaths.
In 2023, the IWK policy reverted to 32 weeks gestation and under for a new vaccine, called nirsevimab. The vaccine is restricted to that group in Nova Scotia, along with infants with high-risk health concerns such as congenital heart disease.
However, nirsevimab is now available for all babies in Ontario and Quebec. That's the kind of universal program Carye Leighton wants in Nova Scotia.
Her two daughters, including one born at 32 weeks gestation in 2017, contracted RSV as babies and were hospitalized. Neither had been eligible for an RSV vaccine.
"It's scary. You feel helpless. There's not much you can do as a parent," said the Halifax mother. "You'll start to see them kind of gasping. You're seeing their collarbone a little bit and then on the ribcage as well, like they're struggling to breathe."
Carye Leighton youngest daugther was born at 32 weeks gestation. (Submitted by Carye Leighton)
A spokesperson for the Department of Health said the province is reviewing an expansion of its publicly funded program for premature infants.
"We are currently reviewing the publicly funded immunization program and considering opportunities to expand it to ensure the best program for all Nova Scotians," the spokesperson said.
The Canadian Paediatric Society said its most recent recommendation is to offer nirsevimab to all infants.
A spokesperson said in an email that the society recommended in 2015 that the cut-off for the old vaccine, palivizumab, be reduced because it "did not appear to be cost-effective" for babies born at 30 to 32 weeks gestation.
"One could have predicted that the number of admissions would increase due to this policy; the increase in Nova Scotia was perhaps higher than expected, possibly because the sample size is relatively small," wrote the spokesperson.
Fabiana Bacchini, executive director of the Canadian Premature Babies Foundation, said providing access to the RSV vaccine for all infants is better than allowing children to get sick and require medical attention.
"We're talking about financial savings for the health-care system, but also for a family perspective. We know how hard it is for families to have those babies back in the hospital," said Bacchini.
In Nova Scotia, people 60 years and older living in long-term care or awaiting long-term care placement are eligible to receive an RSV vaccine for free. A pregnant person in their third trimester can pay out-of-pocket for a vaccine that would also protect their infant.
MORE TOP STORIES
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
FACT FOCUS: RFK Jr.'s reasons for cutting mRNA vaccine not supported by evidence
Although mRNA vaccines saved millions of lives during the COVID-19 pandemic, U.S. Health Secretary Robert F. Kennedy Jr. incorrectly argued they are ineffective to justify the Department of Health and Human Service's recent decision to cancel $500 million in government-funded research projects to develop new vaccines using the technology. The longtime vaccine critic said in an X video posted Tuesday evening that mRNA vaccines do not adequately prevent upper respiratory infections such as COVID-19 and the flu, advocating instead for the development vaccines that use other processes. COVID-19 is the only virus for which real-world data on mRNA vaccine effectiveness is currently available, as mRNA vaccines for other diseases, including the flu, are still under development. The two scientists whose discoveries enabled the creation of mRNA vaccines against COVID-19 won a Nobel Prize in 2023 for their work. Kennedy's claim ignores how mRNA vaccines work, according to experts. They prevent against severe infection and death, but cannot completely prevent an infection from occurring in the first place. Plus, years of research supports the effectiveness of COVID-19 vaccines that use mRNA technology. Here's a closer look at the facts. KENNEDY: 'As the pandemic showed us, mRNA vaccines don't perform well against viruses that infect the upper respiratory tract.' THE FACTS: His claim is contradicted by scientific evidence. Countless studies show that vaccinated individuals fare far better against COVID-19 infections than those who are unvaccinated, while others have estimated that COVID-19 vaccines prevented millions of deaths during the global pandemic. The mRNA vaccines do not prevent respiratory diseases entirely, experts say. Rather, they can prevent more serious illness that leads to complications and death. For example, an mRNA vaccine against COVID-19 may prevent an infection in the upper respiratory tract that feels like a bad cold from spreading to the lower respiratory tract, where it could affect one's ability to breathe. 'A vaccine cannot block a respiratory infection,' said Dr. Jake Scott, an infectious diseases physician and clinical associate professor at Stanford University School of Medicine. 'That's never been the standard for a respiratory virus vaccine. And it's never been the expectation, and it's never been that realistic.' He called Kennedy's claim 'misguided.' Jeff Coller, a professor of RNA biology and therapeutics at Johns Hopkins University, had a similar outlook. 'Vaccinations don't have to be neutralizing, meaning that you're not going to get COVID,' he said. 'But the important part of a vaccination is that they reduce hospitalization and death. And a reduction in hospitalization and death is proof of an effective vaccine.' Vaccines have traditionally required growing viruses or pieces of viruses called proteins and then purifying them. Then a small dose of the vaccine is injected to train the body how to recognize when a real infection hits so it's ready to fight back. But this method takes a long time. The mRNA technology speeds up the process and allows existing vaccines to be updated more quickly. The 'm' in mRNA stands for messenger because the vaccine carries instructions for our bodies to make proteins. Scientists figured out how to harness that natural process for vaccines by making mRNA in a lab. They take a snippet of the genetic code that carries instructions for making the protein they want the vaccine to target. Injecting that snippet instructs the body to become its own mini-vaccine factory, making enough copies of the protein for the immune system to recognize and react. Scott explained that mRNA vaccines are not a 'magic force field' that the immune system can use to block an infection, as it can't detect whether a virus is nearby. It can only respond to a virus that has already entered the body. In the case of COVID-19, this means that the virus could cause an upper respiratory tract infection — a cold, essentially — but would be significantly less likely to cause more severe consequences elsewhere. Myriad studies on the effectiveness of COVID-19 vaccines have been published since they first became available in late 2020. Although protection does wane over time, they provide the strongest barrier against severe infection and death. For example, a 2024 study by the World Health Organization found COVID-19 vaccines reduced deaths in the WHO's European region by at least 57%, saving more than 1.4 million lives since their introduction in December 2020. A 2022 study published in the journal Lancet Infectious Diseases found that nearly 20 million lives were saved by COVID-19 vaccines during their first year. Researchers used data from 185 countries to estimate that vaccines prevented 4.2 million COVID-19 deaths in India, 1.9 million in the United States, 1 million in Brazil, 631,000 in France and 507,000 in the United Kingdom. The main finding — that 19.8 million COVID-19 deaths were prevented — is based on estimates of how many more deaths than usual occurred during the time period. Using only reported COVID-19 deaths, the same model yielded 14.4 million deaths averted by vaccines. Another 2022 study, published in The New England Journal of Medicine, reported that two mRNA vaccines were more than 90% effective against COVID-19. Operation Warp Speed, the federal effort to facilitate the development and distribution of a COVID-19 vaccine, began under the first Trump administration. 'What I don't understand is why is President Trump is allowing RFK Jr. to undermine his legacy that led to a medical intervention that literally saved millions of lives?' Coller said. 'Why is Trump allowing RFK to undermine U.S. leadership in biomedical research and drug development?' ___ Find AP Fact Checks here: Solve the daily Crossword
Forbes
7 hours ago
- Forbes
What Is Legionnaire's Disease? Here's What To Know About New York City Outbreak
At least three people have died in a Legionnaires' disease outbreak in Harlem, authorities said in the most recent update, in the latest summer flare-up of the disease that officials say primarily impacts older people and is potentially linked to poorly maintained cooling towers. People over the age of 50 are at a higher risk of contracting the disease caused by the legionella bacteria, authorities said. Getty Images Legionnaires' is a perennial problem in New York City, especially in buildings that use water cooling towers as part of their air conditioning systems. Most recently, five people died in a 2022 outbreak at the Amsterdam Nursing Home in the Bronx, a 409-bed facility that had been cited by city inspectors seven times in the previous six years for failing to maintain cooling towers, The New York Times reported. The rate of Legionnaires' disease in New York City has steadily risen over the last decade, according to a city Department of Health report published in 2022, with total cases peaking at 656 in 2018. The largest outbreak in New York City's history happened in 2015, when outbreaks of legionella in multiple apartment buildings in the Bronx infected a total of 138 people, killing 16, according to a case study from the National Institutes of Health. Legionnaires' is spread by the legionella bacteria, which causes both the pneumonia-like disease and Pontiac fever. Symptoms include a cough, fever, headaches, muscle aches and shortness of breath, according to the Centers for Disease Control and Prevention. The disease was named after the location of its first identified outbreak—a 1976 American Legion convention at the Bellevue-Stratford Hotel in Philadelphia, which sickened 182 people and led to 29 deaths. How Does Legionnaires' Spread? Legionella grows in certain man-made water systems like showerheads, hot tubs, decorative water features and plumbing systems. It does not grow in window and car air conditioning units, both the CDC and the NYC Health Department confirmed. However, it can grow in large cooling towers for central air conditioning systems, like the kind commonly found on the roofs of buildings in parts of New York City. There is no issue with any building's plumbing system in the impacted parts of Harlem, the Health Department said, and residents can continue using tap water to drink, bathe and cook. Legionnaires' is spread by breathing mist that contains the bacteria, and cannot be spread person-to-person. There is no vaccine to prevent Legionnaires' disease. New York City requires building owners to register their cooling towers and pass routine inspections and testing for the disease. The CDC says legionella thrives in water between 77 degrees Fahrenheit and 113 degrees, and recommends buildings store cold water below 77 degrees and hot water above 140 degrees to prevent the bacteria's growth. Individuals can also take steps to prevent the bacteria's growth, the CDC says, including monitoring their own water heaters' temperature and regularly flushing their units. The agency also recommends regularly cleaning faucets and showerheads, and flushing them by running cold water for at least two minutes, followed by running hot water until it gets hot. Where Else Does Legionnaires' Spread? The Northeast and Midwest recorded the highest rates of Legionnaires' cases in 2019, the most recent year the CDC published a full review. Ohio recorded 785 cases in 2019, and other large states saw similar caseloads: 614 were reported in Illinois, 606 in New York state, 579 in Pennsylvania and 551 in Michigan. Who Is At Risk? People above age 50 are more at risk, according to the NYC Health Department. Over 82% of the 8,890 cases recorded across the country in 2019 occurred in Americans over 50, and men made up 63% of the cases. Black Americans have a higher incidence rate than white people, according to the CDC's data. Smokers, people with chronic lung disease, diabetes, cancer, kidney failure, liver failure, weakened immune systems or are taking medication that weakens the immune system such as drugs for chemotherapy, are all also more at risk. Most cases of Legionnaires' occur in the Northeast and Midwest in the summer and fall months. Key Background At least 67 people have contracted Legionnaires' disease in Central Harlem, the New York City Health Department said in its most recent update. Three deaths have been reported so far, according to authorities. The outbreak is localized in five New York City ZIP codes: 10027, 10030, 10035, 10037 and 10039. 'All cooling towers in the area have been sampled, and work is underway,' Mayor Eric Adams said in a video posted on social media. The city's health department said the risk for most people was low, but warned residents to seek medical attention immediately if they experience flu-like symptoms.
Newsweek
15 hours ago
- Newsweek
RFK Jr. Vaccine Move Alarms Scientists: 'Dangerous Repercussions'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Health Secretary Robert F. Kennedy Jr.'s decision to cancel all federal funding for 22 mRNA vaccine development projects has triggered backlash from scientists, one warning of "dangerous repercussions." Kennedy Jr. announced on Tuesday that the Department of Health and Human Services (HHS) will pull a total of $500 million in funding for the vaccines because "these vaccines fail to protect effectively against upper respiratory infections like COVID and flu." Multiple scientists and doctors have spoken out against this decision with Rick Bright, who led the HHS's Biomedical Advanced Research and Development Authority (BARDA) from 2016 to 2020 saying on X: "A bad day for science, and huge blow to our national security. This decision will have dangerous repercussions." Why It Matters The abrupt end to funding for mRNA vaccines for respiratory viruses—including COVID-19, influenza, RSV, and H5N1 bird flu—represents a marked shift in U.S. health policy. Experts cautioned that the decision would eliminate a critical, proven technology platform, hamper the nation's ability to respond to future pandemics, and signal a prioritization of ideology over scientific evidence. Kennedy has long faced criticism for his position on vaccines. He has insisted he is not opposed to all vaccines, saying he supports "safe vaccines" and he called for parents to consider measles vaccines earlier this year. But he has also made contradictory statements, such as telling podcaster Lex Fridman that there are no safe and effective vaccines. What To Know On Tuesday, the HHS confirmed it would cancel $500 million in mRNA vaccine development contracts, impacting research teams and proposals—including those from Emory University, Tiba Biotech, Pfizer, Sanofi Pasteur and others. "We reviewed the science, listened to the experts, and acted. BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu," Kennedy said in a post on X "We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate." We reviewed the science, listened to the experts, and acted. BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We're shifting that funding toward… — Secretary Kennedy (@SecKennedy) August 5, 2025 Dr. Lucky Tran, a molecular biologist, is one of many who spoke out against the decision on X: "This is so harmful. Scientists are developing mRNA-based cancer vaccines that could save so many lives." Infectious diseases specialist Dr. Jake Scott wrote: "HHS is shutting down BARDA's mRNA vaccine portfolio, with Secretary RFK Jr. claiming the shots 'fail to protect effectively against upper respiratory infections like COVID and flu. That framing is naive and reveals a fundamental misunderstanding of vaccinology. It conflates the unrealistic goal of blocking all infections with the real, achievable goal: reducing serious illness and death. "No vaccine for respiratory viruses—COVID, flu, RSV—provides durable sterilizing immunity. That was never the standard and shouldn't be the expectation. What mRNA vaccines did deliver: the fastest prototype-to-patient timeline in history and a >90% reduction in the risk of invasive ventilation or death. "Ending federal support now sacrifices the very speed and flexibility that saved lives. Science isn't served by abandoning a proven platform because it doesn't do something." Just in: HHS is shutting down BARDA's mRNA vaccine portfolio, with Secretary RFK Jr. claiming the shots 'fail to protect effectively against upper respiratory infections like COVID and flu.' That framing is naive and reveals a fundamental misunderstanding of vaccinology. It… — Jake Scott, MD (@jakescottMD) August 5, 2025 Newsweek has contacted the HHS, via email outside of working hours, for a response to these comments. Supporters of the move included the Children's Health Defense, a nonprofit founded by Kennedy Jr. which focuses on childhood health epidemics but is well-known for its anti-vaccination positions. It said: "CHD applauds this most recent announcement to defund 22 mRNA vaccine projects under BARDA. While we believe that the mRNA shots on the market are unsafe and should be off the market, this is a welcome step in the right direction. The pandemic preparedness industry as it exists today is a threat to human welfare." 🚨BIG NEWS: HHS Winds Down mRNA Vaccine Development Under BARDA 'CHD applauds this most recent announcement to defund 22 mRNA vaccine projects under BARDA. While we believe that the mRNA shots on the market are unsafe and should be off the market, this is a welcome step in the… — Children's Health Defense (@ChildrensHD) August 5, 2025 Before becoming HHS secretary, Kennedy said he would not ban vaccines, telling NBC News in November 2024 that "if vaccines are working for somebody, I'm not going to take them away." "People ought to have choice and ought to be informed by the best information, so I'm going to make sure that scientific safety studies and efficacies are out there and people can make individual assessments about whether that product is going to be good for them." What Happens Next Health policy experts have warned that the effects of the funding termination could deepen if other nations follow the U.S. lead, or if private investment in rapid vaccine development wanes. Researchers cautioned about reduced national readiness for pandemics, with the risk heightened by the ongoing spread of bird flu among livestock and potential biosecurity threats. The full repercussions of the move will likely become clear as the U.S. confronts the next wave of infectious disease threats, and as regulatory, medical, and scientific communities grapple with the loss of federal investment and the uncertainty it brings.
